Shockwave Medical Inc (NASDAQ:SWAV) Director Sells $22,327,500.00 in Stock
Shockwave Medical Inc (NASDAQ:SWAV) Director Antoine Papiernik sold 650,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 4th. The shares were sold at an average price of $34.35, for a total value of $22,327,500.00.
SWAV opened at $31.54 on Friday. The company has a quick ratio of 8.59, a current ratio of 9.13 and a debt-to-equity ratio of 0.10. The company has a 50 day simple moving average of $42.35. Shockwave Medical Inc has a 12 month low of $24.58 and a 12 month high of $68.39.
Shockwave Medical (NASDAQ:SWAV) last posted its quarterly earnings results on Monday, August 5th. The company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.55) by $0.17. The business had revenue of $10.00 million during the quarter, compared to analyst estimates of $8.29 million. Shockwave Medical’s quarterly revenue was up 334.8% on a year-over-year basis. As a group, research analysts forecast that Shockwave Medical Inc will post -2.51 EPS for the current fiscal year.
Several analysts have recently commented on SWAV shares. Canaccord Genuity raised their price target on Shockwave Medical from $50.00 to $65.00 and gave the company a “positive” rating in a report on Tuesday, June 18th. Bank of America reissued a “neutral” rating and issued a $44.00 price target on shares of Shockwave Medical in a report on Thursday, June 13th. Finally, Zacks Investment Research cut Shockwave Medical from a “hold” rating to a “sell” rating in a report on Tuesday, July 9th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and one has given a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $43.50.
About Shockwave Medical
ShockWave Medical, Inc, a medical device company, develops and commercializes intravascular lithotripsy technology to treat calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide. The company offers M5 catheters for treating above-the-knee peripheral artery disease; C2 catheters for treating coronary artery disease; and S4 catheters or treating below-the-knee peripheral artery disease.
Recommended Story: Stock Symbols Definition, Examples, Lookup
Receive News & Ratings for Shockwave Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shockwave Medical and related companies with MarketBeat.com's FREE daily email newsletter.